 |
|
Detection of P-Glycoprotein in Squamous Cell Carcinomas of the Head and Neck
Daniel J. Kelley, MD;
Zlatko P. Pavelic, MD, PhD;
Markus Gapany, MD;
Peter Stambrook, PhD;
Ljiljana Pavelic;
Sabina Gapany;
Jack L. Gluckman, MD
Arch Otolaryngol Head Neck Surg. 1993;119(4):411-414.
Abstract
| |
• One established mechanism of multidrug resistance is elevated expression of P-glycoprotein. The expression of P-glycoprotein by immunohistochemistry was examined in squamous cell carcinomas of the head and neck using a newly developed monoclonal antibody, UIC2, which is specific to the human MDR1 gene product and recognizes an external epitope of the protein. P-glycoprotein was detected in 60% of the samples. MDR1 expression was compared with clinical response to chemotherapy in eight patients who received MDR1-dependent drugs and response was accurately predicted in seven (89%) of eight patients. Positive P-glycoprotein staining correlated with the degree of tumor differentiation, but not with other clinical factors. Therefore, analyzing the expression of P-glycoprotein may play a role when planning chemotherapeutic regimens for patients with head and neck cancer and may be an additional prognostic and diagnostic tool in these patients.
(Arch Otolaryngol Head Neck Surg. 1993;119:411-414)
Author Affiliations
From the Departments of Otolaryngology—Head and Neck Surgery (Drs Kelley, Z. P. Pavelic, M. Gapany, and Gluckman, and Mss L. Pavelic and S. Gapany) and Anatomy and Cell Biology (Dr Stambrook), College of Medicine, University of Cincinnati (Ohio).
Footnotes
Accepted for publication September 15, 1992.
Read before the Third International Conference on Head and Neck Cancer, San Francisco, Calif, July 26, 1992.
Reprint requests to Department of Otolaryngology—Head and Neck Surgery, College of Medicine, University of Cincinnati, 231 Bethesda Ave, Cincinnati, OH 45267-0528 (Dr Pavelic).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
